Indeed, TRIB2 has been identified as a candidate biomarker for melanoma diagnosis and progression, because it exhibits low expression in healthy skin samples, increases in benign melanoma, with the highest expression seen in malignant melanoma samples [78]. Here, TRIB2 is linked to melanoma.